Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Poland Pharmaceuticals Industry
SWOT — 6
Poland Political SWOT — 7
Poland Economic SWOT — 7
Poland Business Environment
SWOT — 8
Pharmaceutical Business Environment
Ratings — 9
Table: Central And Eastern Europe Business
Environment Ratings For Q409 — 9
Limits Of Potential
Returns — 10
Risks To Realisation Of
Returns — 10
Market Summary — 12
Regulatory Regime — 13
Intellectual Property
Developments — 14
Pricing And
Reimbursement — 16
Wholesale
Margins — 18
Pharmacy Margins — 18
Pricing & Reimbursement Developments — 19
Marketing — 21
Other Regulatory
Developments — 22
Industry
Developments — 24
Healthcare
Overview — 24
Healthcare Reforms — 25
Health Insurance — 27
Epidemiology — 28
Table: Disease Burden In
CEE — 29
Research And Development — 30
Industry Forecast Scenario — 32
Overall Market
Forecast — 32
Table: Poland’s Drug Market
Indicators, Historical Data and Forecasts — 33
Key Growth
Factors – Industry — 34
Table: Poland’s Health
Expenditure Indicators — 35
Key Growth Factors –
Macroeconomic — 36
Table: Poland - Economic Activity, 2006
– 2013 — 38
Prescription Market
Forecast — 39
Table: Poland – Prescription Market
Indicators, Historical Data and Forecasts (US$mn unless otherwise
stated) — 40
Patented Market
Forecast — 41
Table: Poland’s Patented Market
Forecast, Historical Data and Forecasts — 42
Generics
Market Forecast — 43
Table: Poland’s Generics Market
Indicators, Historical Data and Forecasts — 44
OTC
Medicine Market Forecast — 45
Table: OTC Market
Indicators, Historical Data and Forecasts (US$mn unless otherwise
stated) — 47
Medical Device Market
Forecast — 48
Table: Poland’s Medical Device Market
Indicators, 2004-2013 (US$bn unless otherwise stated) — 49
Trade Figures — 50
Table: Poland’s Pharmaceutical
Trade Indicators, 2004-2013 (US$mn) — 51
Other Healthcare
Data Forecasts — 51
Table: Socio-Demographic Indicators,
2004-2013 — 51
Key Risks To BMI’s Forecast
Scenario — 52
Competitive
Landscape — 53
Domestic Industry — 53
Domestic Company Developments — 54
Foreign
Industry — 55
Foreign Company
Developments — 56
Biotechnology
Sector — 58
Wholesale Sector — 58
Retail Sector — 61
Table: Poland’s Pharmacies And
Pharmacy Market Ratios, 2004-2009 — 62
Company
Monitor — 63
GlaxoSmithKline — 63
Eli
Lilly — 65
Gedeon Richter — 66
Krka — 68
Lek (Novartis/Sandoz) — 70
Polpharma — 72
Country Snapshot: Poland Demographic
Data — 75
Section 1: Population — 75
Table: Demographic Indicators, 2005-2030 — 75
Table:
Rural/Urban Breakdown, 2005-2030 — 76
Section 2: Education
And Healthcare — 76
Table: Education,
2002-2005 — 76
Table: Vital Statistics,
2005-2030 — 76
Section 3: Labour Market And Spending
Power — 77
Table: Employment Indicators,
2001-2006 — 77
Table: Consumer Expenditure, 2000-2012
(US$) — 77
Table: Average Annual Wages,
2000-2012 — 78
BMI Forecast
Modelling — 79
How We Generate Our Pharmaceutical Industry
Forecasts — 79
Pharmaceutical Business Environment Ratings
Methodology — 80
Ratings Overview — 80
Table: Pharmaceutical Business Environment Indicators — 81
Weighting — 82
Table: Weighting Of
Components — 82
Sources — 82
| 
View Cart
